

# Fibrosis Program Patents

## METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE

Country	Application No.	Date Filed	Status
Australia	2017248273	16/10/2018	Filed
Canada	3020327	05/10/2018	Filed
Europe	17779836	05/11/2018	Filed
Hong Kong	19128046	12/08/2019	Filed
U.S.	62/320,151	08/04/2016	Filed
U.S.	16/089,234	27/09/2018	Filed

## METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING AN IL-33 ANTAGONIST

Country	Application No.	Date Filed	Status
Australia	2016226414	15/09/2017	Filed
Canada	2,978,449	29/02/2016	Filed
Europe	16759325	25/09/2017	Filed
Hong Kong	18107063.7	30/05/2018	Filed
U.S.	15/555,027	15/12/2017	Granted 10/12/2019 ( <a href="#">US10500273B2</a> )

## METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING A TNF RECEPTOR 2 ANTAGONIST

Country	Application No.	Date Filed	Status
Australia	2016226415	18/09/2017	Filed
Canada	2,978,431	29/02/2016	Filed
Europe	16759326.8	25/09/2017	Filed
Hong Kong	18107062.8	30/05/2018	Filed
U.S.	15/555,030	31/08/2017	Filed

# Fibrosis Program Patents

## METHOD OF TREATING OCULAR FIBROSIS USING AN IL-33/TNF BISPECIFIC ANTIBODY

Country	Application No.	Date Filed	Status
U.S.	62/722,263	24/08/2018	Filed

## METHOD OF TREATING LOCALIZED FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY

Country	Application No.	Date Filed	Status
U.S.	16/328,979	27/02/2019	Filed
Europe	17924768.9	01/04/2019	Filed

## METHOD OF TREATING SYSTEMIC FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY

Country	Application No.	Date Filed	Status
U.S.	16/329,013	27/02/2019	Filed
Europe	17847574.5	01/04/2019	Filed
Hong Kong	62020001194	09/01/2020	Filed

## METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS INCLUDING DUPUYREN'S WITH ONE OR MORE SPECIFIC HUMAN MMP AND ATNF ANTAGONIST

Country	Application No.	Date Filed	Status
U.S.	61/845,366	11/07/2013	Filed

## USES OF IL-33 RECEPTORS ANTAGONIST

Country	Application No.	Date Filed	Status
U.S.	62/127,157	02/03/2015	Filed

## Fibrosis Program Patents (cont'd)

TREATMENT FOR DUPUYTREN'S DISEASE					
Country	Application No.	Date Filed/Granted	Status	Patent Number	Note
Australia	2011322482	06/07/2017	Granted	2,011,322,482	
Australia	2017204267	05/09/2019	Granted	2,017,204,267	
Canada	2,847,197	28/02/2014	Filed		
<b>The European patent valid or being validated in:</b>					
Europe	11779628.4	20/02/2019	Granted	E-1075071	Austria
Europe	11779628.4	12/02/2019	Granted	2,362,446	Belgium
Europe	11779628.4	14/02/2019	Granted	60 2011 054 785.2	Germany
Europe	11779628.4	07/03/2019	Granted	2,362,446	Finland
Europe	11779628.4	09/01/2019	Granted	2,362,446	France
Europe	11779628.4	07/03/2019	Granted	2,362,446	Iceland
Europe	11779628.4	02/01/2019	Granted	2362446-IE	Ireland
Europe	11779628.4	11/03/2019	Granted	502,019,000,019,925	Italy
Europe	11779628.4	12/02/2019	Granted	2,362,446	Netherlands
Europe	11779628.4	28/02/2019	Granted	2,362,446	Norway
Europe	11779628.4	11/03/2019	Filed		Spain
Europe	11779628.4	28/02/2019	Granted	2,362,446	Sweden
Europe	11779628.4	26/02/2019	Granted	2,362,446	Switzerland/Liechtenstein
Europe	11779628.4	21/12/2018	Granted	2,362,446	United Kingdom
Japan	2013-535462	16/09/2016	Granted	6004494	
U.S.	16/399,547	02/06/2020	Granted	10669334	

## Fibrosis Program Patents (cont'd)

### METHODS OF PREVENTION OR TREATMENT OF TRIGGERED INFLAMMATORY REACTIONS USING TNF ALPHA ANTAGONIST

Country	Application No.	Date Granted	Status	Patent Number	Note
Europe	11710004	03/06/2020	Granted	2,547,363	Austria
Europe	11710004	03/06/2020	Granted	2547363	Belgium
Europe	11710004	03/06/2020	Granted	2547363	Switzerland
Europe	11710004	03/06/2020	Granted	602,011,067,119	Germany
Europe	11710004	03/06/2020	Granted	DK/EP 2547363	Denmark
Europe	11710004	03/06/2020	Granted	2547363	Spain
Europe	11710004	03/06/2020	Granted	2547363	Finland
Europe	11710004	03/06/2020	Granted	2547363	France
Europe	11710004	03/06/2020	Granted	2547363	Ireland
Europe	11710004	03/06/2020	Granted	2547363	Italy
Europe	11710004	03/06/2020	Granted	2547363	Netherlands
Europe	11710004	03/06/2020	Granted	2547363	Norway
Europe	11710004	03/06/2020	Granted	2547363	Sweden
Europe	11710004	03/06/2020	Granted	2547363	United Kingdom

### METHOD FOR TREATMENT OF POST OPERATIVE COGNITIVE DYSFUNCTION

Country	Application No.	Grant Date	Status	Patent Number	Note
U.S.	13/579,555	12/04/2016	Granted	9,308,254	
Japan	2012-553396	24/06/2016	Granted	5,955,227	

# SCA Program Patents

## SCA: CYCLOHEXYL COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES

Country	Application No.	Date Filed/Granted	Status	Note
US2	10239848	26/03/2019	Granted	Claims directed to a method for treating obesity or a disease/disorder associated therewith by administration of a compound of the formula as defined in claim 1 – issued.
US3	11,149,014B2	19/10/2021	Granted	Claims directed to a method for treating pain or associated condition or symptom by administration of a compound of the formula as defined in claim 1
IL	248256	31/07/2018	Granted	Claims directed to a pharmaceutical composition for treatment of (i) obesity or a disease/disorder associated therewith; or (ii) abnormal food consumption or body weight, or a condition or symptom associated therewith, comprising a compound of the formula 1 as defined in claim 1
Europe	EP3134393 B1	09/12/2020	Granted	Claims directed to a pharmaceutical composition for use in the treatment of chronic pain. Valid in: Austria, Belgium, Germany, Finland, France, Iceland, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland/Liechtenstein and the United Kingdom.
CN	ZL201580020978.7	14/01/2020	Granted	This invention relates to phenyl substituted cyclohexenyl compounds, compositions comprising them and uses thereof for the preparation of medicaments as defined in claim 1
CA	CA2944837A1	26/10/2021	Granted	Claims directed to use of HU-435 or a salt thereof, e.g. the molecule salt thereof (HU-436), for the preparation of a pharmaceutical composition for treatment of chronic pain.

## SCA: CANNABINOID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION AND/OR PAIN AND/OR OBESITY

Country	Application No.	Date Filed/Granted	Status	Note
	PCT/IL2021/051398	24/11/2021	Filed	PCT filed via EPO, priority date 24 Nov, 2020

## SCA: BIOACTIVE PHENOLATE IONIC COMPLEXES

Country	Application No.	Date Filed/Granted	Status	Note
	PCT/IL2021/05045	21/04/2021	Filed	PCT filed via EPO, priority date 22 Apr, 2020

# a7nAChR Program Patents

a7nAChR				
Country	Date Filed/Granted	Status	Patent/Application Number	Note
US Grant	16/09/2014	Granted	US8835391B2	Alpha B-crystallin as a therapy for multiple sclerosis
US Grant	25/01/2011	Granted	US7875589B2	Alpha B-crystallin as a therapy for rheumatoid arthritis
US Application	16/09/2019	Filed	US20180333451A1	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components.
Japan	18/11/2016	Filed	2018-526196	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components.
Canada	18/11/2016	Filed	3004908	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components.